







▶ Volume 28, Issue 8 ▶ The effect of mandatory generic substitu

Current Medical Research and Opinion > Volume 28, 2012 - Issue 8

339 8

Views CrossRef citations to date Altmetric

Osteoporosis: Original Article

The effect of mandatory generic substitution on the safety of alendronate and patients' adherence

Pauline Siew Mei Lai

✓, Siew Siang Chua, Yah Huei Chong & Siew Pheng Chan Pages 1347-1355 | Accepted 26 Jun 2012, Published online: 16 Jul 2012

66 Cite this article ▶ https://doi.org/10.1185/03007995.2012.708326

Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Full Article

Figures & data

References

66 Citations

Metrics

Reprints & Permissions

Read this article

Share

Abstra

Objectiv

Generic

generic

practice

medica

*Apotex

tMerck S

Researc

This pro

We Care About Your Privacy

We and our 912 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting "I Accept" enables tracking technologies to support the purposes shown under "we and our partners process data to provide," whereas selecting "Reject All" or withdrawing your consent will disable them. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the ["privacy preferences"] link on the bottom of the webpage [or the floating icon on the bottom-left of the webpage, if applicable]. Your choices will have effect within our Website. For more details, refer to our Privacy Policy. Here

We and our partners process data to provide:

I Accept

Reject All

Show Purpose clinical

and

nate

quality of

osteopolotic women prescribed once-weekly rosamax (proprietary group) but were

switched to apo-alendronate after 2 years ('switched over' group); and (2) patients initiated with once-weekly apo-alendronate (generic group). Participants were recruited from the Osteoporosis Clinic of a tertiary hospital. Data were collected through interviews.

Main outcome measures:

Side-effects and medication adherence.

Results:

Alendrona

A total of 131 participants were recruited: proprietary group = 64 and generic group = 67. An intergroup and a within-group comparison were made. Side-effects were reported by 6 (9.4%), 30 (44.8%) and 12 (18.8%) participants in the proprietary, generic and 'switched over' groups, respectively. Participants who were on generic alendronate were at a significantly higher risk of experiencing side-effects compared to those who were taking proprietary alendronate [odds ratio (OR):7.84 (95% CI: 2.98–20.65), p < 0.001]. However, no significant statistical difference was found between the 'switched over' and the proprietary group [OR: 2.23 (95% CI: 0.78–6.37), p = 0.127]. Four out of 12 (33.3%) patients who experienced side-effects immediately after switching to generic alendronate discontinued generic alendronate due to intolerable

ice to gastroin X generic Conclus Medicati d similar although more likely the switch to exper the cost of from p nate are the t equivale Keywords

Transparency

Declaration of funding

Funding for research - none.


Declaration of financial/other relationships

The authors declare that they have no competing interests. CMRO peer reviewers on this manuscript have no relevant financial relationships to disclose.

Acknowledgments

We would like to record our appreciation to the staff of the Osteoporosis Clinic of the hospital under study for their assistance and cooperation. Last but not least, we would like to thank all the participants for their involvement in this study.

This material has not been previously published except as an abstract in the 2nd International Conference on Pharmacy and Advanced Pharmaceutical Sciences, Yogyakarta, Indonesia, 19–20 July 2011, abstract no P10: 64.



Information for Open access **Authors** Overview R&D professionals Open journals Editors Open Select Librarians **Dove Medical Press** Societies F1000Research Opportunities Help and information Reprints and e-prints Help and contact Advertising solutions Newsroom Accelerated publication Corporate access solutions Keep up to date Register to receive personalised research and resources by email X or & Francis Group Copyright orma business